Clinical trials
Latent Tuberculosis trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 39 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 5 |
| Hanyang University | 3 |
| Germans Trias i Pujol Hospital | 2 |
| JHP Pharmaceuticals LLC | 2 |
| ANRS, Emerging Infectious Diseases | 1 |
| All India Institute of Medical Sciences | 1 |
| Asan Medical Center | 1 |
| Assiut University | 1 |
| Assuta Hospital Systems | 1 |
| Centro Hospitalar do Oeste | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Latent Tuberculosis | 39 |
| Tuberculosis | 21 |
| Acquired Immunodeficiency Syndrome | 3 |
| HIV Infections | 3 |
| Communicable Diseases | 2 |
| Tuberculosis, Pulmonary | 2 |
| Arachnoiditis | 1 |
| Arthritis, Rheumatoid | 1 |
| COVID-19 | 1 |
| Diabetes Mellitus | 1 |
Trials
Showing 51 to 39 of 39. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.